Seeking Alpha
View as an RSS Feed

Bret Jensen  

View Bret Jensen's Comments BY TICKER:
A, AA, AAPL, ABB, ABT, ABTL, ABX, ACLS, ACMP, ACTG, ACTV, ADBE, ADSK, AEP, AGCO, AGEN, AGU, AHH, AHT, AIG, AKS, ALJ, ALL, ALR, AMAT, AMGN, AMKR, AMTD, AMZG, AMZN, ANF, ANV, APA, APC, APL, ARCP, ARII, ARLP, ARO, ARP, ATRS, ATSG, ATVI, ATW, AU, AVGO, AVNR, AXAS, AXTI, AYR, AZN, BA, BAC, BAS, BAX, BBBY, BBEP, BBRY, BBT, BBW, BBY, BCEI, BGFV, BHI, BIDU, BIG, BIIB, BIOL, BK, BKCC, BKH, BKW, BLK, BMO, BMR, BNS, BP, BRCD, BRCM, BRKS, BTU, BWP, BX, BYI, C, CALL, CAT, CBI, CBOU, CDE, CELG, CEO, CERS, CGIX, CGR, CHK, CHL, CHMT, CJES, CLDT, CLF, CLMT, CLR, CMG, CMI, CMLP, CNAT, CNDO, CNP, CNQ, CNX, COF, COG, COH, COOL, COP, CORT, CPE, CPIX, CPSI, CRM, CROX, CRUS, CRZO, CSCO, CSX, CTCM, CVE, CVS, CVX, CXPO, CXS, CY, DAKT, DAN, DBC, DD, DDE, DECK, DENN, DG, DISH, DK, DNR, DO, DOW, DRH, DRIV, DSCO, DTLK, DTV, DUSA, DVAX, DVN, DVR, DWA, DXLG, E, EBAY, ECA, EDR, ELLI, ELY, EMC, END, ENDP, EOG, EOX, EPAM, EPAX, EPB, EPR, EQIX, EQM, EROC, ESIO, ESV, ETE, ETN, ETP, ETRM, EVEP, EWZ, EXK, EXLP, EXPE, EXXI, F, FANG, FB, FCH, FCX, FDX, FIG, FLL, FLY, FOLD, FOSL, FRD, FSC, FSII, FURX, FWLT, FXCM, GBX, GCOM, GE, GEF, GEOY, GERN, GES, GEVA, GFI, GILD, GLP, GLUU, GLW, GM, GNW, GOOG, GOOGL, GPOR, GPS, GS, GSK, GSM, GSS, GTATQ, GTE, HAL, HBM, HCBK, HCLP, HEP, HERO, HES, HFC, HIG, HL, HLF, HLX, HMA, HON, HOS, HP, HPQ, HPT, HRS, HRZN, HTA, HTGC, HURN, HZNP, IACI, IAG, IGTE, IMOS, INN, INT, INTC, INVN, IO, IPGP, IQNT, IRDM, IRET, IRT, ISRG, ITRI, ITT, IVAN, JAZZ, JDSU, JNJ, JNPR, JOY, JPM, KBH, KBR, KCG, KEG, KERX, KFY, KKR, KLAC, KLIC, KO, KOG, KONA, KR, KRG, KRO, LAD, LCI, LGCY, LIFE, LIME, LINE, LLL, LLNW, LLY, LMOS, LMT, LNCO, LNKD, LO, LOCO, LOW, LPRI, LSI, LUK, LULU, LVS, LXP, LYB, M, MANT, MCEP, MCHX, MCP, MDR, MDT, MELI, MEMP, MET, MHR, MITL, MMLP, MMP, MNK, MO, MOD, MOS, MPC, MPO, MPW, MRCY, MRGE, MRK, MRO, MRVL, MS, MSFT, MT, MTDR, MTOR, MTSN, MU, MUR, MXIM, MYL, MYRG, NAVB, NBL, NBR, NE, NEE, NEM, NEON, NFLX, NFX, NGLS, NGPC, NILE, NOG, NOK, NOV, NSC, NSPH, NTAP, NTSP, NUAN, NVAX, NVDA, NVS, NWY, NXPI, NYCB, NYX, OAS, OCN, OCZ, OHI, OIS, OKS, OPEN, OPLK, ORAN, ORCL, ORIG, ORLY, OUTR, OVTI, OXY, OZM, PAA, PAAS, PACD, PACR, PANW, PAYX, PBF, PBH, PBI, PBY, PCLN, PDH, PDLI, PDS, PEET, PEG, PES, PETM, PETS, PFE, PFMT, PGEM, PH, PM, PNG, PNK, PNRA, POM, POT, PRTA, PSX, PTEN, PULB, PVR, PWER, QCCO, QCOM, QLGC, QLTY, QRE, QUMU, R, RAIL, RAX, RCL, RDWR, REGN, RES, REXX, RF, RFMD, RIG, RIGL, RIO, RNN, ROC, ROSE, ROVI, RPRX, RRD, RSTI, RTEC, RTN, RUE, RUTH, RVBD, SAM, SARA, SBRA, SCLN, SCMR, SCO, SDRL, SEAC, SFY, SHOR, SIGA, SIMG, SIMO, SIRI, SKUL, SLB, SLCA, SM, SMCI, SN, SNH, SNY, SODA, SPLK, SPLS, SPN, SPPI, SPRT, SPY, SQNM, SSH, SSNLF, STI, STJ, STMP, STO, STT, STX, SUNE, SVU, SWFT, SWKS, SYNA, SYRG, T, TAL, TAP, TBT, TCAP, TDW, TEF, TER, TESO, TEVA, TEX, TGX, TICC, TIVO, TKR, TLLP, TOT, TPC, TPLM, TQNT, TRLG, TRN, TSLA, TSO, TST, TSYS, TTI, TWI, TWX, UA, UNH, UNIS, UPL, USB, V, VALE, VELTF, VICL, VLO, VMW, VNR, VOD, VRA, VXX, VZ, WAC, WAG, WDC, WEN, WFC, WFT, WHR, WIFI, WLL, WMT, WRES, XEC, XOM, XRX, YELP, YHOO, Z, ZAGG, ZEUS, ZIXI, ZLTQ, ZNGA
Latest  |  Highest rated
  • The Makings Of A Biotech Bubble [View article]
    Thanks. Yes, the names you cited should be much less volatile than the small cap arena should we get a correction in the sector. Happy Hunting.
    Jun 18, 2015. 06:30 AM | Likes Like |Link to Comment
  • The Makings Of A Biotech Bubble [View article]
    GILD is long term holding at approximately 11 times forward earnings one of the few biotechs that is still very cheap.
    Jun 17, 2015. 04:03 PM | 7 Likes Like |Link to Comment
  • 2 Biotechs Under $5 That Could Light Up In 2015 [View article]
    No worries. There has been a slew of these this year and glad this was one of the inaugural picks of the just launched BiotechGems (http://bit.ly/1G3z2Kc) portfolio. Not as big as EGRX, AVNR, or AGEN yet but on the right path....Hopefully we get pullback in sector and SGYP gets down under $6 again where it would be a buy again. Happy Hunting.
    Jun 17, 2015. 10:27 AM | 2 Likes Like |Link to Comment
  • Finding Small Cap Gems Within Biotech [View article]
    Results from a Phase 1 single ascending dose study in 40 healthy volunteers of Prothena's (NASDAQ:PRTA) monoclonal antibody for the potential treatment of Parkinson's disease (PD), PRX002, demonstrated mean reductions of free serum alpha-synuclein of up to 96%. The results were highly statistically significant (p<0.00001). No serious adverse events or hypersensitivity reactions were reported. The highest dose administered was 30 mg/kg.Alpha-synuclein is a protein found in the blood, cerebrospinal fluid (CSF) and the brain. PD patients have decreased levels of the protein in the CSF, believed to be due to the accumulation of pathogenic alpha-synuclein in the brain which plays a role in neurodegeneration.A Phase 1 multiple ascending dose trial in PD patients is ongoing.Prothena established a global collaboration with Roche (OTCQX:RHHBY) in December 2013 to develop and commercialize alpha-synuclein-targeting antibodies, including PRX002. To date, Prothena has received $45M of the potential $600M in milestones specified in the agreement. Prothena has the option to co-promote PRX002 in the U.S. where the companies will share the development and commercial costs and profits on a 30/70 basis (PRTA: 30%; Roche: 70%). Roche as exclusive rights ex-U.S. and will pay Prothena up to double-digit royalties on commercial sales.
    Jun 17, 2015. 08:26 AM | 1 Like Like |Link to Comment
  • 2 Biotechs Under $5 That Could Light Up In 2015 [View article]
    Small cap Synergy Pharmaceuticals (NASDAQ:SGYP) is up 50% premarket on light volume in response to its announcement of positive results in a Phase 3 clinical trial evaluating plecanatide for the treatment of patients with chronic ideopathic constipation (CIC).Preliminary analysis shows that both doses of plecanatide, 3 mg and 6 mg, met the primary endpoint of the proportion of patients in the intent-to-treat population who were durable overall responders versus placebo during the 12-week treatment period. Specifically, the results were: 3 mg arm: 21.0%; 6 mg arm: 19.5%; placebo: 10.2% (p<0.001).The durable overall responder endpoint is the current FDA metric for approval for CIC. Plecanatide would be the first drug cleared under this more stringent criterion.Plecanatide is an analog of uroguanylin, a gastrointestinal hormone produced in the small intestine that plays a key role in the normal functioning of the digestive tract.The company intends to file an New Drug Application (NDA) with the FDA in Q4.
    Jun 17, 2015. 08:24 AM | Likes Like |Link to Comment
  • Agenus: Even After Rally; Shares Still Have Upside [View article]
    Interesting
    Jun 16, 2015. 09:18 PM | 1 Like Like |Link to Comment
  • Agenus: Even After Rally; Shares Still Have Upside [View article]
    Interesting play. Worth a small position. Have order in. Thanks for bringing this one to my attention.
    Jun 16, 2015. 02:42 PM | 1 Like Like |Link to Comment
  • Chicago Bridge & Iron: Buy The Dip [View article]
    In the short run the market is a voting mechanism, in the long run it is a weighing mechanism.
    Jun 16, 2015. 01:15 PM | Likes Like |Link to Comment
  • Micron Technologies: Tide Will Turn In Second Half Of 2015 [View article]
    On a pure number basis, but not on ROE at all. Would you rather make $2 million profit annually on $10 million worth of investment or $3 million on a $40 million investment?
    Jun 16, 2015. 01:11 PM | 7 Likes Like |Link to Comment
  • My Current Thoughts And Strategies Around Biotech [View article]
    Not one I have followed closely. Seems like recent setback and broken stock at the moment.
    Jun 15, 2015. 02:22 PM | Likes Like |Link to Comment
  • Revisiting The Investment Case On Progenics Pharmaceuticals [View article]
    Usually I just let it run with 90% of stake. Happy Hunting.
    Jun 14, 2015. 09:05 AM | 1 Like Like |Link to Comment
  • Revisiting The Investment Case On Progenics Pharmaceuticals [View article]
    Passage from piece I put to address this dilemma on huge winner Eagle Pharma seems appropriate here.

    This seems an appropriate time to re-emphasize a couple of core philosophies I try to consistently articulate to subscribers in high beta sectors especially biotech. The first is that this is an extremely complicated sector of the market prone to bouts of exuberance usually followed by fear induced pull backs like that of last March. The fact is most new drugs never make it out of the approval process, leading to high rates of failure. Hundreds of companies are spending tens of billions a year to develop new compounds. In 2014, the FDA only approved 41 new drugs.
    This is why I believe one must practice what I have dubbed "shotgun investing" over the years in this volatile area in the market. This consists of taking myriad small positions in a variety of promising but speculative companies in the space. One must go into this exercise knowing that there will be quite a few flameouts along the way. However, the occasional grand slam like Eagle will lead to a solid return over time.
    Second, one must know when to take some profits on winners. There are three mistakes that can crater an investor's overall returns over time in the small cap biotech arena. The first is when a stock implodes because a company's compound fails in trials. Unfortunately, there is not much you can do about that outside of initial research and maintaining a well-diversified portfolio.
    The second mistake is when a stock like Eagle soars and you take no profits along the way. Many times, these rockets come back to Earth and you feel like a darn fool for not taking some gains. However, the biggest mistake is cashing out entirely. Having an equity with a $250 million market capitalization grow to being worth $1 billion in short order is a great feeling. Cashing out completely and watching the same company grow to a $10 billion or bigger behemoth is a sickening one.
    This is why I have developed the "Jensen Rules" to force myself to employ a prudent investing strategy in this volatile area of the market. After a 50% return, I cash out 10% of my original share position. If the stock doubles, I take 20% more of the original stake off the table. If I am lucky enough to get a triple, I sell the last 20% of the original position. This leaves me with half of my original position riding on the "house's money" after booking a guaranteed gain on the position even if the stock goes to zero. As importantly, it keeps me from throwing away the next Gilead Sciences (NASDAQ: GILD).
    Jun 13, 2015. 11:47 AM | 7 Likes Like |Link to Comment
  • Chances Of June Swoon Increasing [View article]
    Difference between is conservative and liberal economic policies is simply this....conservative trying to drive economic activity to grow the overall pie, liberal policies are concentrated on how to divide the pie.
    Jun 13, 2015. 11:45 AM | 2 Likes Like |Link to Comment
  • Chances Of June Swoon Increasing [View article]
    You can't see the forest for the trees. Most all cities are liberal by nature. However, the ones that are doing the best are located pro-growth red states (Austin, Denver, Nashville, SLC, etc..)....the ones that are going broke (Detroit, Baltimore, Chicago) are in one party cities in blue or purple pro union states...
    Jun 13, 2015. 11:43 AM | 2 Likes Like |Link to Comment
  • Chances Of June Swoon Increasing [View article]
    Like Baltimore, Chicago, Providence, Newark, Detroit, etc...?
    Jun 11, 2015. 07:21 PM | 2 Likes Like |Link to Comment
COMMENTS STATS
11,305 Comments
12,489 Likes